Mark Salter

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease
    Mark Salter
    Global Project Management, Bldg 1, GlaxoSmithKline, Park Rd, Ware SG12 0DP, UK
    Am J Physiol Lung Cell Mol Physiol 293:L660-7. 2007
  2. ncbi request reprint Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method
    Mike Barker
    RI CEDD, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
    J Med Chem 48:4507-10. 2005

Collaborators

  • Stuart N Farrow
  • Keith Biggadike
  • Mike Barker
  • Philip A Skone
  • Haydn T Jones
  • John M Pritchard
  • Francois Pacquet
  • Michael J Johnston
  • Davina Humphreys
  • Iain M McLay
  • Simon J F Macdonald
  • Victoria M Vinader
  • Margaret Clackers
  • Derek A Demaine
  • Stephen E Shanahan
  • Iain Uings

Detail Information

Publications2

  1. ncbi request reprint Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease
    Mark Salter
    Global Project Management, Bldg 1, GlaxoSmithKline, Park Rd, Ware SG12 0DP, UK
    Am J Physiol Lung Cell Mol Physiol 293:L660-7. 2007
    ..In conclusion, the potent and selective pharmacological profile of FF described here could deliver an effective, safe, and sustained topical treatment of respiratory inflammatory diseases such as allergic rhinitis and asthma...
  2. ncbi request reprint Design and synthesis of new nonsteroidal glucocorticoid modulators through application of an "agreement docking" method
    Mike Barker
    RI CEDD, GlaxoSmithKline Medicines Research Centre, Stevenage, UK
    J Med Chem 48:4507-10. 2005
    ..The method was validated by the syntheses of 9 and related analogues, which are potent binders of GR. 15a is a partial agonist while 9e and 15a are micromolar antagonists in a mouse mammary tumor virus transactivation assay...